| Ticker: ABTG | 5 Park Plaza, Suite 770 | |
| Exchange: NASDAQ-Small Cap Market | Irvine, California 92614 | |
| Industry: Manufacturing | (714) 224-2555 |
| Type of Shares: | Common Shares | Filing Date: | 6/4/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 8/14/96 | |
| Non-U.S. Shares: | 0 | Filing Price: | $5.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $5.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.40 | |
| Offering Amount: | $15,000,000 | Selling: | $0.20 | |
| Expenses: | $870,000 | Reallowance: | $0.10 | |
| Shares Out After: | 11,000,000 |
| Manager | Tier | Phone |
| M.H. Meyerson & Company | Lead Manager | (201) 332-3353 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 3/31/96 | 3/31/96 | ||||
| Revenue: | $0.00 | Assets: | $1.16 | ||
| Net Income: | -$1.34 | Liabilities: | $0.52 | ||
| EPS: | -$0.16 | Equity: | $0.64 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company develops pharmaceutical versions of natural medicines, using technology it has developed for "fingerprinting" natural medicines. The company's technology, concepts and procedures for standardizing the manufacture of natural medicines into pharmaceuticals have been developed over the past 20 years in laboratories of the UNiversity of Southern California School of Medicine by Dr. Tasneem A. Khwaja. The Fingerprinting Technology is designed to enable the company to precisely describe the identity and measure the quantity of bioactivity of each active component in the natural medicine. The company believes that the Fingerprinting Technology provides the information necessary to seek patent protection and, together with the results of preclinical trials, if any, United States Food and Drug Administration approval for each pharmaceutical version of the natural medicine. |
| Use of Proceeds |
| The proceeds of the offering will be used for preclinical and clinical testing of T4GEN and n-T4GEN, to manufacture T4GEN and n-T4GEN for clinical trials and to develop manufacturing procedures and protocols; for research and development of new pharmaceuticals, for marketing and administrative expenses for the Fingerprinting technology, to construct and operate a contract fingerprinting facility for the Fingerprinting technology, for payment of deferred compensation, to repay short-term debt, and for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.